Fiserv Inc. Common Stock vs Guardant Health Inc. Common Stock — how do they compare? Fiserv Inc. Common Stock trades at $46.29 (market cap $24.81B), while Guardant Health Inc. Common Stock trades at $162.64 (market cap $21.74B). The key difference: Fiserv Inc. Common Stock and Guardant Health Inc. Common Stock are close in size by market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Fiserv Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiserv Inc. Common Stock for 0 Days and Guardant Health Inc. Common Stock for 3 Days on average.
| FISV | GH | |
|---|---|---|
Market Cap | $24.81B | $21.74B |
Volume | 4,091,234 | 1,297,295 |
Sector | Technology | Health |
52-Week High | $126.54 | $187.22 |
52-Week Low | $44.36 | $64.19 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $52.60B | $22.38B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fiserv, Inc. is a global provider of payments and financial services technology, offering merchant acquiring, digital commerce, and financial solutions through its Merchant Solutions and Financial Solutions segments.
Read more on FISV →Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →